C
hiodini and colleagues (1) reported that increased levels of cortisol secretion are related to diabetes complications but did not evaluate central nervous system complications. It has been increasingly recognized that diabetes is related to several neurological and psychiatric disorders. Mild cognitive impairment, Alzheimer's disease, and depression have been associated with diabetes, and these are also related to abnormal cortisol levels. The discovery of how hypercortisolism is related to diabetes complications could help us understand these associations.
It has been known that Cushing's syndrome (a hypercortisolemic condition) is related to neuropsychological impairment, probably mediated by cortisol deleterious effects in the brain (2) . Moreover, treatment of depression in diabetic patients has led to improvement in glycemic and diabetes complications (3). Glucocorticoid-related memory impairment has been linked to glucocorticoid receptors in the hippocampus (4), and it is said that cortisol predicts cognitive functions (5) . Glucocorticoids have been shown to increase the pathogenic features of Alzheimer's disease (6) , and in addition, rosiglitazone, an insulin sensitizer, has shown to reverse memory deficits in a transgenic model of Alzheimer's disease by reducing glucocorticoid actions (7). Earlier, Sandeep et al. (8) showed that blocking 11␤-hydroxisteroid dehydrogenase, which normally regenerates cortisone to cortisol, improved cognitive performance in a diabetic group.
In light of the finding made by Chiodini et al. (1) , cortisol should become a focal point in researching diabetes complications.
